Traditional biologics, new biotherapeutics modalities and biosimilars are flooding discovery and development pipelines. Thus, analytical function is rapidly evolving, demanding high-throughput and high-resolution tools, focused biomolecular and biophysical assays, and rapid analytical and impurity profiling strategies. The Analytics & Impurities pipeline features in-depth perspectives on the latest developments and most critical steps in characterization of biologics, stability issues arising from particles, impurities, immunogenicity, protein aggregates and their impact on stability and safety of biopharmaceuticals.
Elizabeth M. Topp, PhD, Dane O. Kildsig Chair and Department Head, Department of Industrial and Physical Pharmacy, Purdue University
Paolo Arosio, PhD, Professor, Biochemical Engineering, Department of Chemistry and Applied Biosciences, ETH Zurich
Peter Schurtenberger, PhD, Professor, Department of Chemistry, Lund University